Table 1.
Pathways enriched for non-synonymous SNPs in the TCGA data
| Molecular Function/Pathway | Enrichment Rank by p-value* | Enrichment P-value (BH corrected) | Enrichment level (observed/expected) | Pathway mutational spectrum:% of genes | Pathway Mutational Prevalence: % of tumors | # genes mutated in at least 3 patients | |
|---|---|---|---|---|---|---|---|
| KEGG |
ECM-receptor Interaction |
1 |
3.35x10-11 |
~4.5X |
74% (62/84) |
40% (127/316) |
30 |
| |
Focal Adhesion |
2 |
2.62x10-9 |
~2.9X |
(61%) 122/199 |
58% (183/316) |
45 |
| |
Calcium Signaling |
3 |
2.05x10-8 |
~2.9X |
63% (112/179) |
48% (153/316) |
40 |
| Gene Ontology |
Cell Adhesion |
1 |
1.03x10-25 |
~2.5X |
64% (366/576) |
89% (281/316) |
156 |
| |
Developmental process |
14 |
1.03x10-15 |
~1.5X |
49% (430/869) |
90% (284/316) |
375 |
| Extracellular Matrix | 19 | 2.56x10-14 | ~2.8X | 53% (80/150) | 40% (127/316) | 76 |
*Enriched pathways from all genes with predicted mutations in at least 3 ovarian tumors from the TCGA data were ranked by pvalue and selected pathways reported here.